Press Releases

Date	Title	PDF Version
May 31, 2016	Alexion to Present at Upcoming Investor Conferences
May 19, 2016	Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress
May 04, 2016	Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Apr 28, 2016	Alexion Reports First Quarter 2016 Results
Apr 12, 2016	Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016
Apr 04, 2016	Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physical Function in Children with Hypophosphatasia (HPP) Receiving Long-Term Treatment with Strensiq® (asfotase alfa)
Mar 28, 2016	Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Mar 03, 2016	New Data Presented at WORLDSymposium™ 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma™ (sebelipase alfa)
Mar 01, 2016	SBC-103 (rhNAGLU enzyme) Shows a 26.2 Percent Mean Reduction in Heparan Sulfate in Cerebrospinal Fluid at the Highest Dose Studied in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) in Phase 1/2 Study at Six Months
Feb 29, 2016	Alexion to Present at Upcoming Investor Conferences

Search